- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Fractyl Health reports Q3 resultsa | 1 | Seeking Alpha | ||
| FRACTYL HEALTH Aktie jetzt für 0€ handeln | |||||
| 12.11. | Fractyl Health, Inc.: Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | 100 | GlobeNewswire (Europe) | REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024... ► Artikel lesen | |
| 04.11. | Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 04.11. | Fractyl Health, Inc.: Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 | 122 | GlobeNewswire (Europe) | Single Revita procedure led to sustained, clinically meaningful weight loss in majority of patients with Type 2 Diabetes REMAIN-1 weight maintenance pivotal study on-track to report mid-point data... ► Artikel lesen | |
| 29.10. | Fractyl Health, Inc.: Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 | 1 | GlobeNewswire (USA) | ||
| 28.10. | Fractyl Health, Inc.: Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 24.09. | Fractyl Health, Inc.: Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference | 1 | GlobeNewswire (USA) | ||
| 14.09. | Fractyl Health president sells over $188k in company stock | 14 | Investing.com | ||
| 03.09. | Fractyl Health, Inc.: Fractyl Health to Participate in Upcoming September Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 14.08. | Fractyl Health, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 07.08. | Fractyl Health, Inc.: Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 | 1 | GlobeNewswire (USA) | ||
| 30.07. | Fractyl gets FDA breakthrough device status for Revita | 1 | Seeking Alpha | ||
| 30.07. | Fractyl Health, Inc.: Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs | 81 | GlobeNewswire (Europe) | Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or... ► Artikel lesen | |
| 30.07. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Fractyl Health, Inc.: Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day | 1 | GlobeNewswire (USA) | ||
| 24.06. | Fractyl Health, Inc.: Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates | 1 | GlobeNewswire (USA) | ||
| 24.06. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Fractyl Health Presents Preclinical Data On Rejuva GLP-1 Gene Therapy | 1 | RTTNews | ||
| 23.06. | Fractyl Health, Inc.: Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at ... | 3 | GlobeNewswire (USA) | ||
| 20.05. | Fractyl Health, Inc.: Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 | 183 | GlobeNewswire (Europe) | Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,90 | +0,28 % | Kursziel erhöht: BioNTech: Kaufchance nach Kennedy-Schock? | © Foto: picture alliance / Laci Perenyi | Laci PerenyiVergangene Woche war keine gute Woche für Impfstoff-Aktien. Ist das die Kaufgelegenheit für Anleger?Die Nominierung des impfkritischen Robert F.... ► Artikel lesen | |
| CUREVAC | 2,566 | +0,63 % | CureVac mit BRANDNEUER Prognose: Steht die Aktie jetzt vor einem Kursdebakel - Das müssen Sie unbedingt beachten! | ||
| AMGEN | 282,65 | -0,05 % | Dividendenbekanntmachungen (18.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0569 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0,19 CAD 0,128 EUR ALLISON TRANSMISSION... ► Artikel lesen | |
| NOVAVAX | 8,130 | +0,02 % | NOVAVAX INC - 8-K, Current Report | ||
| BIOGEN | 151,90 | +0,20 % | UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study | WESTON (dpa-AFX) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant... ► Artikel lesen | |
| MAINZ BIOMED | 0,202 | +1,10 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest der nächsten Generation für den globalen Markt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 13,715 | -0,11 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
| VIKING THERAPEUTICS | 50,74 | +0,48 % | Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up - Here's Why | ||
| BIOCRYST PHARMACEUTICALS | 7,286 | -0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Launches ORLADEYO (berotralstat) in Ireland | ||
| CARDIOL THERAPEUTICS | 1,552 | 0,00 % | Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association | - Eine
deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten
- Anzahl... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,742 | +1,09 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
| EXELIXIS | 34,000 | -0,58 % | 22,070 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Navellier & Associates Inc. | ||
| SAREPTA THERAPEUTICS | 105,00 | -4,28 % | Sarepta Therapeutics Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Sarepta Therapeutics (SRPT):Earnings: $33.6 million in Q3 vs. -$40.9 million in the same period last year.
EPS: $0.34 in Q3 vs.... ► Artikel lesen | |
| VAXART | 0,578 | -0,35 % | Vaxart, Inc.: Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | - 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator... ► Artikel lesen | |
| EXACT SCIENCES | 49,840 | -1,85 % | Cathie Wood's ARK buys Tempus AI stock, sells Exact Sciences |
FRACTYL HEALTH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+0,97 %) liegt der Kurs bei 2,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FRACTYL HEALTH INC finden Sie auf Wallstreet Online.
